The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Open accessAbstract
BACKGROUND: Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in previously untreated patients with advanced melanoma has not been tested in a phase 3 controlled study. METHODS: We randomly assigned 418 previously untreated patients who had metastatic melanoma without a BRAF mutation to receive nivolumab (at a dose of 3 mg per kilogram of body weight every 2 weeks and dacarbazine-matched placebo every 3 weeks) or dacarbazine (at a dose of 1000 mg per square meter of body-surface area every 3 weeks and nivolumab-matched placebo every 2 weeks). The primary end point was overall survival. RESULTS: At 1 year, the overall rate of survival was 72.9% (95% confidence interval [CI], 65.5 to 78.9) in the nivolumab group, as compared with 42.1% (95% CI, 33.0 to 50.9) in the dacarbazine group (hazard ratio for death, 0.42; 99.79% CI, 0.25 to 0.73; P<0.001). The median progression-free survival was 5.1 months in the nivolumab group versus 2.2 months in the dacarbazine group (hazard ratio for death or progression of disease, 0.43; 95% CI, 0.34 to 0.56; P<0.001). The objective response rate was 40.0% (95% CI, 33.3 to 47.0) in the nivolumab group versus 13.9% (95% CI, 9.5 to 19.4) in the dacarbazine group (odds ratio, 4.06; P<0.001). The survival benefit with nivolumab versus dacarbazine was observed across prespecified subgroups, including subgroups defined by status regarding the programmed death ligand 1 (PD-L1). Common adverse events associated with nivolumab included fatigue, pruritus, and nausea. Drug-related adverse events of grade 3 or 4 occurred in 11.7% of the patients treated with nivolumab and 17.6% of those treated with dacarbazine. CONCLUSIONS: Nivolumab was associated with significant improvements in overall survival and progression-free survival, as compared with dacarbazine, among previously untreated patients who had metastatic melanoma without a BRAF mutation. (Funded by Bristol-Myers Squibb; CheckMate 066 ClinicalTrials.gov number, NCT01721772.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“however responses to these therapies are often heterogeneous and not durable (1–3).”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [3]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment with immunotherapy targeting checkpoint inhibitors PD-1 or CTLA-4 significantly increases survival in patients with metastatic melanoma over other standards of care [1, 2]”
From Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients (2019) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While immune checkpoint inhibitors (ICIs) have greatly enhanced clinical outcomes across multiple cancer types,1, 2, 3”
From irAE-GPT: leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets (2026) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, the responses to ICI treatment have still been observed in those with low or undetectable levels of PD-L1 expression.9”
From The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti–Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC (2019) · cites this paper as [9]
In the citing paper
“Immune checkpoint blockade with monoclonal antibodies (mAbs) targeting programmed cell death protein 1 (PD-1) provides long-term clinical benefits to nearly 40% of patients with advanced melanoma (1–5).”
From Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients (2021) · cites this paper as [3]
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Self-citationHauschild, A., Grob, J., Демидов, Л. В., Jouary, T., Gutzmer, R., Millward, M. J., Rutkowski, P. L., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 3,050
Self-citationTopalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,205
Self-citationSurvival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1200/JCO.2013.51.4802 · DOI · Paper page
Cited by
Sorted by citations
Items 901–1,000 of 1,032
Ballerini, M., Galié, S., Tyagi, P., Catozzi, C., Raji, H., Nabinejad, A., Macandog, A. D. G., Cordiale, A., Slivinschi, B. I., Kugiejko, K. K., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01318-z · Cited by 98
Atkins, M. B., & Larkin, J. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv414 · Cited by 92
Wang, X., Feng, Y.-Y., Bajaj, G., Gupta, M., Agrawal, S., Yang, A., Park, J.-S., Lestini, B. J., & Roy, A. K. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12133 · Cited by 91
Estimated Healthcare Costs of Melanoma in Australia Over 3 Years Post-Diagnosis
Elliott, T. M., Whiteman, D. C., Olsen, C. M., & Gordon, L. G. (2017) · Applied Health Economics and Health Policy · doi:10.1007/s40258-017-0341-y · Cited by 92
β-Catenin–mediated immune evasion pathway frequently operates in primary cutaneous melanomas
Nsengimana, J., Laye, J. P., Filia, A., O'Shea, S. J., Muralidhar, S., Poźniak, J., Droop, A., Chan, M., Walker, C., Parkinson, L., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95351 · Cited by 96
Mechanisms of Intrinsic Tumor Resistance to Immunotherapy
Rieth, J. M., & Subramanian, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051340 · Cited by 92
Iivanainen, S., Ahvonen, J., Knuuttila, A., Tiainen, S., & Koivunen, J. P. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000531 · Cited by 92
Castello, A., Rossi, S., Mazziotti, E., Toschi, L., & Lopci, E. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.237768 · Cited by 91
Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment
Robatel, S., & Schenk, M. (2022) · Cancers · doi:10.3390/cancers14040985 · Cited by 94
Cell Surface CD74–MIF Interactions Drive Melanoma Survival in Response to Interferon-γ
Tanese, K., Hashimoto, Y., Berkova, Z., Wang, Y., Samaniego, F., Lee, J. E., Ekmekçioglu, S., & Grimm, E. A. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.204 · Cited by 91
Kleponis, J., Skelton, R. A., & Zheng, L. (2015) · Europe PMC (PubMed Central) · doi:10.7497/j.issn.2095-3941.2015.0046 · Cited by 91
Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma
Ivashko, I. N., & Kolesar, J. (2016) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140768 · Cited by 95
Sun, X., Shi, B., Zheng, H., Min, L., Yang, J., Li, X., Liao, X., Huang, W., Zhang, M., Xu, S., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0303-9 · Cited by 95
Potential biomarker for checkpoint blockade immunotherapy and treatment strategy
Dong, Z., Wu, S.-P., Liao, R.-Q., Huang, S., & Wu, Y.-L. L. C. (2016) · Tumor Biology · doi:10.1007/s13277-016-4812-9 · Cited by 90
Alexander, W. (2016) · PubMed Central · Cited by 90
Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes
Miyoshi, Y., Ogawa, O., & Oyama, Y. (2016) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.239.155 · Cited by 90
Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors
Gomes, J. R., Schmerling, R. A., Haddad, C. K., Racy, D. J., Ferrigno, R., Gil, E., Zanuncio, P. H. D. R., & Buzaid, A. C. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000141 · Cited by 90
Fang, T., Alvelid, J., Spratt, J., Ambrosetti, E., Testa, I., & Teixeira, A. I. (2021) · ACS Nano · doi:10.1021/acsnano.0c10632 · Cited by 91
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
Chang, E., Pelosof, L. C., Lemery, S. J., Gong, Y. U. T., Goldberg, K. B., Farrell, A. T., Keegan, P., Veeraraghavan, J., Wei, G., Blumenthal, G. M., et al. (2021) · The Oncologist · doi:10.1002/onco.13887 · Cited by 94
Heidelberger, V., Goldwasser, F., Kramkimel, N., Jouinot, A., Huillard, O., Boudou, P., Chanal, J., Arrondeau, J., Franck, N., Alexandre, J., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0464-x · Cited by 92
Melanoma classification and management in the era of molecular medicine
Rashid, S., Shaughnessy, M., & Tsao, H. (2022) · Dermatologic Clinics · doi:10.1016/j.det.2022.07.017 · Cited by 92
Lipid-based nanosystems: the next generation of cancer immune therapy
Cheng, Z., Fobian, S., Gurrieri, E., Amin, M., D’Agostino, V., Falahati, M., Zalba, S., Debets, R., Garrido, M. J., Saeed, M., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01574-1 · Cited by 95
Anti-PD1-induced collagenous colitis in a melanoma patient
Baroudjian, B., Lourenço, N., Pagès, C., Chami, I., Maillet, M., Bertheau, P., Bagot, M., Gornet, J., Lebbé, C., & Allez, M. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000252 · Cited by 90
Self-citationKazandjian, D. G., Keegan, P., Suzman, D. L., Pazdur, R., & Blumenthal, G. M. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.01.001 · Cited by 90
Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma
Patel, K. R., Martinez, A. P., Stahl, J. M., Logan, S. J., Perricone, A. J., Ferris, M. J., Buchwald, Z. S., Chowdhary, M., Delman, K. A., Monson, D. K., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1442168 · Cited by 89
Combination anti–PD-1 and antiretroviral therapy provides therapeutic benefit against SIV
Mylvaganam, G., Chea, L. S., Tharp, G. K., Hicks, S. L., Velu, V., Iyer, S. S., Deléage, C., Estes, J. D., Bosinger, S. E., Freeman, G. J., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122940 · Cited by 89
Radiotherapy and immunotherapy: a synergistic effect in cancer care
Turgeon, G., Weickhardt, A. J., Azad, A., Solomon, B., & Siva, S. (2018) · The Medical Journal of Australia · doi:10.5694/mja2.12046 · Cited by 89
Immune checkpoint inhibitors‐induced neuromuscular toxicity: From pathogenesis to treatment
Psimaras, D., Velasco, R., Birzu, C., Tamburin, S., Lustberg, M. B., Bruna, J., & Argyriou, A. A. (2019) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12339 · Cited by 90
An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies
Cao, J., Chen, L., Li, H., Chen, H., Yao, J., Mu, S., Liu, W., Zhang, P., Cheng, Y., Liu, B., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0236 · Cited by 89
Leveraging Transcriptional Dynamics to Improve BRAF Inhibitor Responses in Melanoma
Smalley, I., Kim, E., Li, J., Spence, P., Wyatt, C. J., Eroglu, Z., Sondak, V. K., Messina, J. L., Babacan, N. A., Maria–Engler, S. S., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.09.023 · Cited by 92
PD‐1 Pathway Inhibitors: Immuno‐Oncology Agents for Restoring Antitumor Immune Responses
Medina, P. J., & Adams, V. R. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1714 · Cited by 90
Kakavand, H., Vilain, R. E., Wilmott, J. S., Burke, H., Yearley, J. H., Thompson, J. F., Hersey, P., Long, G. V., & Scolyer, R. A. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.110 · Cited by 90
Self-citationImmunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies
Komatsubara, K. M., & Carvajal, R. D. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0606-5 · Cited by 89
Jiang, X., Seo, Y. D., Chang, J. H., Coveler, A. L., Nouri-Nigjeh, E., Pan, S., Jalikis, F. G., Yeung, R. S. W., Crispe, I. N., & Pillarisetty, V. G. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1333210 · Cited by 88
Lopez, A. T., & Geskin, L. J. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0128 · Cited by 88
Cardiotoxicity of Immune Checkpoint Inhibitors
Zhang, L., Jones‐O’Connor, M., Awadalla, M., Zlotoff, D. A., Thavendiranathan, P., Groarke, J. D., Villani, A., Lyon, A. R., & Neilan, T. G. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0731-6 · Cited by 89
A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer
Sullivan, R. J., Hollebecque, A., Flaherty, K. T., Shapiro, G. I., Rodon, J. A., Millward, M., Zhang, W., Gao, L., Sykes, A. K., Willard, M. D., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0681 · Cited by 88
Zhao, X., Shen, J., Ivaturi, V. D., Gopalakrishnan, M., Feng, Y., Schmidt, B. J., Statkevich, P., Goodman, V. L., Gobburu, J. V. S., Bello, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.015 · Cited by 88
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
Massironi, S., Pilla, L., Elvevi, A., Longarini, R., Rossi, R. E., Bidoli, P., & Invernizzi, P. (2020) · Cells · doi:10.3390/cells9030688 · Cited by 88
New approaches for targeting platinum-resistant ovarian cancer
McMullen, M., Madariaga, A., & Lheureux, S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.013 · Cited by 88
Ribas, A., Algazi, A. P., Ascierto, P. A., Butler, M. O., Chandra, S., Gordon, M. S., Hernandez-Aya, L. F., Lawrence, D. P., Lutzky, J., Miller, W. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19810-w · Cited by 92
Self-citationImmunotherapy in non-small cell lung cancer: Past, present, and future directions
Punekar, S. R., Shum, E., Grello, C., Lau, S. C. M., & Velcheti, V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.877594 · Cited by 89
Immune-mediated drug-induced liver injury: immunogenetics and experimental models
Gerussi, A., Natalini, A., Antonangeli, F., Mancuso, C., Agostinetto, E., Barisani, D., Di Rosa, F., Andrade, R., & Invernizzi, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094557 · Cited by 87
Mooradian, M. J., Nasrallah, M., Gainor, J. F., Reynolds, K. L., Cohen, J. V., Lawrence, D. P., Miloslavsky, E. M., Kohler, M. J., Sullivan, R. J., & Schoenfeld, S. R. (2018) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2018.10.012 · Cited by 87
Petrelli, F., Ardito, R., Merelli, B., Lonati, V., Cabiddu, M., Seghezzi, S., Barni, S., & Ghidini, A. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000520 · Cited by 89
Mahadevan, D., Lanasa, M. C., Farber, C. M., Pandey, M. K., Whelden, M., Faas, S. J., Ulery, T. L., Kukreja, A., Li, L., Bedrosian, C. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0710-1 · Cited by 87
Melanoma Treatments and Mortality Rate Trends in the US, 1975 to 2019
Kahlon, N., Doddi, S., Yousif, R., Najib, S., Sheikh, T., Abuhelwa, Z., Burmeister, C., & Hamouda, D. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.45269 · Cited by 91
IL-2 based cancer immunotherapies: an evolving paradigm
Rokade, S., Mehta-Damani, A., Oft, M., & Emmerich, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1433989 · Cited by 88
Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody
Nagaya, T., Nakamura, Y., Sato, K., Harada, T., Choyke, P. L., Hodge, J. W., Schlom, J., & Kobayashi, H. (2016) · Oncotarget · doi:10.18632/oncotarget.12410 · Cited by 88
Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy
Viale, G., Trapani, D., & Curigliano, G. (2017) · BioMed Research International · doi:10.1155/2017/4719194 · Cited by 89
Takeuchi, Y., Tanemura, A., Tada, Y., Katayama, I., Kumanogoh, A., & Nishikawa, H. (2017) · International Immunology · doi:10.1093/intimm/dxx073 · Cited by 88
Kim, R., Keam, B., Kim, S., Kim, M., Kim, S. H., Kim, J., Kim, Y. J., Kim, T. M., Jeon, Y. K., Kim, D., et al. (2019) · BMC Cancer · doi:10.1186/s12885-018-5214-8 · Cited by 87
Abdel-Rahman, O. M., Elhalawani, H. M., & Fouad, M. (2015) · Immunotherapy · doi:10.2217/imt.15.87 · Cited by 87
Immune-checkpoint blockade — durable cancer control
Buchbinder, E. I., & Hodi, F. S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.237 · Cited by 87
The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer
McLachlan, J., Boussios, S., Okines, A. F. C., Glaessgen, D., Bodlar, S., Kalaitzaki, R., Taylor, A., Lalondrelle, S., Gore, M. E., Kaye, S. B., et al. (2016) · Clinical Oncology · doi:10.1016/j.clon.2016.10.002 · Cited by 85
Kim, S. T., Klempner, S. J., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., Kang, W. K., Kim, K.-M., & Lee, J. (2017) · Oncotarget · doi:10.18632/oncotarget.20492 · Cited by 85
Hurkmans, D. P., Basak, E. A., van Dijk, T. C., Mercieca, D., Schreurs, M. W. J., Wijkhuijs, A. J. M., Bins, S., Hoop, E. O., Debets, R., Joerger, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0669-y · Cited by 90
Regev, A., Avigan, M., Kiazand, A., Vierling, J. M., Lewis, J. H., Omokaro, S. O., Bisceglie, A. M. D., Fontana, R. J., Bonkovsky, H. L., Freston, J. W., et al. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102514 · Cited by 86
Immunotherapy With Radiotherapy and Chemoradiotherapy for Cervical Cancer
Feng, C. H., Mell, L. K., Sharabi, A. B., McHale, M. T., & Mayadev, J. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2020.05.003 · Cited by 86
Is There a Role for Immunotherapy in Prostate Cancer?
Rizzo, A., Mollica, V., Cimadamore, A., Santoni, M., Scarpelli, M., Giunchi, F., Liang Cheng, C., Antonio Lopez-beltran, B., Fiorentino, M., Montironi, R., et al. (2020) · Cells · doi:10.3390/cells9092051 · Cited by 85
Helm, A., Tinganelli, W., Simoniello, P., Kurosawa, F., Fournier, C., Shimokawa, T., & Durante, M. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.09.041 · Cited by 86
Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors
Zhong, L., Wu, Q., Chen, F., Liu, J., & Xie, X. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02803-5 · Cited by 87
Diab, A. K., Gogas, H. J., Sandhu, S. K., Long, G. V., Ascierto, P. A., Larkin, J., Sznol, M., Franke, F. A., Ciuleanu, T., Pereira, C., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00172 · Cited by 85
Self-citationUveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition
Sun, M. M., Levinson, R. D., Filipowicz, A., Anesi, S. D., Kaplan, H. J., Wang, W., Goldstein, D. A., Gangaputra, S. S., Swan, R. T., Sen, H. N., et al. (2019) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2019.1577978 · Cited by 85
Therapeutic Advances and Treatment Options in Metastatic Melanoma
Johnson, D. B., & Sosman, J. A. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0565 · Cited by 85
Heppt, M. V., Eigentler, T., Kähler, K. C., Herbst, R. A., Göppner, D., Gambichler, T., Ulrich, J., Dippel, E., Loquai, C., Schell, B., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1856-z · Cited by 84
Tanaka, R., Maruyama, H., Tomidokoro, Y., Yanagiha, K., Hirabayashi, T., Ishii, A., Okune, M., Inoue, S., Sekine, I., Tamaoka, A., et al. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyw090 · Cited by 84
Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium
Willis, B. C., Sloan, E. A., Atkins, K. A., Stoler, M. H., & Mills, A. M. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.67 · Cited by 85
Current status and perspectives in immunotherapy for metastatic melanoma
Marconcini, R., (IMI), F. T. I. M. I., Spagnolo, F., Stucci, L. S., Ribero, S., Marra, E., Rosa, F. D., Picasso, V., Guardo, L. D., Cimminiello, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23746 · Cited by 84
Pluim, D., Ros, W., van Bussel, M. T. J., Brandsma, D., Beijnen, J. H., & Schellens, J. H. M. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.10.025 · Cited by 84
Wang, S., Zhang, J., He, Z., Wu, K., & Liu, X. (2019) · International Journal of Cancer · doi:10.1002/ijc.32327 · Cited by 85
Guo, L., Wei, R., Lin, Y., & Kwok, H. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01508 · Cited by 85
Mucosal Melanoma: Pathological Evolution, Pathway Dependency and Targeted Therapy
Ma, Y., Xia, R., Ma, X., Judson‐Torres, R. L., & Zeng, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.702287 · Cited by 88
Immune Checkpoint Inhibitors in Cancer Therapy—How to Overcome Drug Resistance?
Lao, Y., Shen, D., Zhang, W., He, R., & Jiang, M. (2022) · Cancers · doi:10.3390/cancers14153575 · Cited by 87
Zhong, W., Lu, Y., Han, X., Yang, J., Qin, Z., Zhang, W., Yu, Z., Wu, B., Liu, S., Xu, W., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113224 · Cited by 85
Tandon, P., Bourassa‐Blanchette, S., Bishay, K., Parlow, S., Laurie, S. A., & McCurdy, J. D. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000213 · Cited by 85
Sarcoid-like reactions in patients receiving modern melanoma treatment
Dimitriou, F., Frauchiger, A. L., Urosevic‐Maiwald, M., Nägeli, M., Goldinger, S. M., Barysch, M. J., Franzen, D., Kamarachev, J., Braun, R. P., Dummer, R., et al. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000437 · Cited by 84
Nonomura, Y., Otsuka, A., Nakashima, C., Seidel, J. A., Kitoh, A., Dainichi, T., Nakajima, S., Sawada, Y., Matsushita, S., Aoki, M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1248327 · Cited by 83
Immune Checkpoint Inhibitors Side Effects and Management
Kourié, H. R., & Klastersky, J. A. (2016) · Immunotherapy · doi:10.2217/imt-2016-0029 · Cited by 83
Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management
Goldman, J. W., Mendenhall, M. A., & Rettinger, S. R. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0519 · Cited by 83
Correlation between patients' age and cancer immunotherapy efficacy.
Wu, Q., Wang, Q., Tang, X., Xu, R., Zhang, L., Chen, X., Xue, Q., Wang, Z., Shi, R., Wang, F., et al. (2019) · Europe PMC (PubMed Central) · doi:10.1080/2162402x.2019.1568810 · Cited by 84
Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer’s Achilles’ Heel
Caracciolo, D., Riillo, C., Martino, M. T. D., Tagliaferri, P., & Tassone, P. (2021) · Cancers · doi:10.3390/cancers13061392 · Cited by 87
PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression
Filippone, A., Lanza, M., Mannino, D., Raciti, G., Colarossi, C., Sciacca, D., Cuzzocrea, S., & Paterniti, I. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03130-z · Cited by 85
Wang, B., Yin, H., Zhang, Y., Zhao, Q., Wang, H., Wei, J., Meng, L., Xin, Y., & Jiang, X. M. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01073-9 · Cited by 85
Luo, Z., Mei, J., Wang, X., Wang, R., He, Z., Geffen, Y., Sun, X., Zhang, X., Xu, J., Wan, R., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114697 · Cited by 85
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab
Eroglu, Z., Kim, D. W., Wang, X., Camacho, L. H., Chmielowski, B., Seja, E., Villanueva, A., Ruchalski, K. L., Glaspy, J. A., Kim, K. B., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.012 · Cited by 87
Challenge of Prognostic Uncertainty in the Modern Era of Cancer Therapeutics
Temel, J. S., Shaw, A. T., & Greer, J. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.8573 · Cited by 84
Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC
Brockwell, N. K., Owen, K. L., Zanker, D. J., Spurling, A., Rautela, J., Duivenvoorden, H. M., Baschuk, N., Caramia, F., Loi, S., Darcy, P. K., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0150 · Cited by 83
Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis
Franklin, C., Rooms, I., Fiedler, M., Reis, H., Milsch, L., Herz, S., Livingstone, E., Zimmer, L., Schmid, K. W., Dittmer, U., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.09.019 · Cited by 84
Self-citationImmunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition
Siefker-Radtke, A. O., & Curti, B. D. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.190 · Cited by 82
Noncoding RNAs as potential mediators of resistance to cancer immunotherapy
Vishnubalaji, R., Shaath, H., Elango, R., & Alajez, N. M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.006 · Cited by 82
Immunocompetent cancer-on-chip models to assess immuno-oncology therapy
Maulana, T. I., Kromidas, E., Wallstabe, L., Cipriano, M., Alb, M., Zaupa, C., Hudecek, M., Fogal, B., & Loskill, P. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.015 · Cited by 86
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
Diab, A. K., Tykodi, S. S., Daniels, G. A., Maio, M., Curti, B. D., Lewis, K. D., Jang, S., Kalinka‐Warzocha, E., Puzanov, I. J., Spira, A. I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00675 · Cited by 83
Self-citationT-cell repertoire diversity: friend or foe for protective antitumor response?
Porciello, N., Franzese, O., D’Ambrosio, L., Palermo, B., & Nisticò, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02566-0 · Cited by 88
Increasing the safety and efficacy of chimeric antigen receptor T cell therapy
Li, H., & Zhao, Y. (2017) · Protein & Cell · doi:10.1007/s13238-017-0411-9 · Cited by 83
Dai, J., Belum, V. R., Wu, S., Sibaud, V., & Lacouture, M. E. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.06.044 · Cited by 82
Fujimura, T., Kambayashi, Y., Tanita, K., Sato, Y., Hidaka, T., Otsuka, A., Tanaka, H., Furudate, S., Hashimoto, A., & Aiba, S. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14273 · Cited by 82
Beyond Melanoma: Inhibiting The PD-1/PD-L1 Pathway in Solid Tumors
Gentzler, R. D., Hall, R. D., Kunk, P. R., Gaughan, E. M., Dillon, P. M., Slingluff, C. L., & Rahma, O. E. (2016) · Immunotherapy · doi:10.2217/imt-2015-0029 · Cited by 81
Munakata, W., Ohashi, K., Yamauchi, N., & Tobinai, K. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2101-4 · Cited by 81
PD-L1 Expression in Tumor Metastasis is Different Between Uveal Melanoma and Cutaneous Melanoma
Javed, A., Arguello, D., Johnston, C., Gatalica, Z., Terai, M., Weight, R. M., Orloff, M. M., Mastrangelo, M. J., & Sato, T. (2017) · Immunotherapy · doi:10.2217/imt-2017-0066 · Cited by 81
Metadata
- Authors
- Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., Savage, K. J., Hernberg, M. M., Lebbé, C., Charles, J., Mihalcioiu, C., Chiarion-Sileni, V., Mauch, C., Cognetti, F., Arance, A., Schmidt, H., Schadendorf, D., Gogas, H., Lundgren-Eriksson, L., Horak, C., Sharkey, B., Waxman, I. M., Atkinson, V., & Ascierto, P. A.
- Affiliations
- Inserm (FR)
- The University of Sydney (AU)
- Cabrini Hospital (AU)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- University of Siena (IT)
- Hôpital Claude Huriez (FR)
- University Hospital Heidelberg (DE)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Royal Prince Alfred Hospital (AU)
- The authors' affiliations are listed in the Appendix.
- BC Cancer Agency (CA)
- Helsinki University Hospital (FI)
- Royal Victoria Hospital (CA)
- Centrum für Integrierte Onkologie (DE)
- Instituto Nazionale Tumori Regina Elena (IT)
- Hospital Clínic de Barcelona (ES)
- Aarhus University Hospital (DK)
- University of Duisburg-Essen (DE)
- National and Kapodistrian University of Athens (GR)
- Bristol-Myers Squibb (United States) (US)
- Greenslopes Private Hospital (AU)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- ORCID
- Robert, Caroline
- Long, Georgina V.
- Dutriaux, Caroline
- Maio, Michele
- Mortier, Laurent
- Hassel, Jessica C.
- Rutkowski, Piotr
- McNeil, Catriona
- Savage, Kerry J.
- Hernberg, Micaela M.
- Charles, Julie
- Mihalcioiu, Catalin
- Mauch, Cornelia
- Cognetti, Francesco
- Arance, Ana
- Schmidt, Henrik
- Schadendorf, Dirk
- Gogas, Helen
- Atkinson, Victoria
- Ascierto, Paolo A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-01-22
- Volume
- 372
- Issue
- 4
- Pages
- 320-330
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2128035403
- Semantic Scholar
- 6a8a53c7f9fd79ff959c6101698e58d58ff6123e
- Cited by
- 5,519
- References
- 25
- Citations by year
- 2026: 154 · 2025: 230 · 2024: 293 · 2023: 335 · 2022: 430 · 2021: 516 · 2020: 601 · 2019: 586 · 2018: 642 · 2017: 715 · 2016: 614 · 2015: 373
- FWCI
- 274.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- nivolumab, metastatic melanoma, BRAF wild-type melanoma, dacarbazine, immune checkpoint inhibitors, PD-1 inhibitors, overall survival, progression-free survival, objective response rate, PD-L1 expression, treatment-naive patients, adverse events, immunotherapy versus chemotherapy, subgroup analysis
- MeSH terms
- Nivolumab, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Dacarbazine, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Survival Rate, Disease-Free Survival, Proto-Oncogene Proteins B-raf, Young Adult, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
